Read on nature.comBiotech Investor Jim O'Neill Nominated to Lead US National Science Foundation
President Donald Trump plans to nominate biotechnology investor Jim O'Neill to lead the National Science Foundation (NSF), one of the largest funders of basic US research. This marks a significant departure from tradition, as O'Neill would be the first non-scientist or engineer to head the agency. He inherits an NSF facing substantial challenges, including a 30% staff reduction, budget uncertainty, and the recent abrupt resignation of its previous director. The nomination has raised questions about the future direction of the agency and its role in funding fundamental scientific discovery.
In a move that signals a potential shift in the leadership of American science, President Donald Trump plans to nominate biotechnology investor Jim O'Neill to be the next director of the National Science Foundation (NSF). This nomination, confirmed by a White House spokesperson to Nature, places a figure with a background in finance and government administration at the helm of one of the nation's premier agencies for funding basic research. The NSF has been operating without a permanent leader since the resignation of director Sethuraman Panchanathan in April 2025.
A Departure from Tradition
If confirmed by the US Senate, Jim O'Neill would break a long-standing precedent. He would be the first leader of the NSF who is not a scientist or an engineer. All of his predecessors brought direct research and development experience to the role. Neal Lane, who led the NSF from 1993 to 1998, expressed concern about this shift, noting it "will be a major concern of the [science and technology] community," which relies on the discoveries funded by the agency. O'Neill holds humanities degrees from Yale University and the University of Chicago.
Despite his non-scientific academic background, O'Neill is familiar with the corridors of federal science policy. He served in various administrative roles at the US Department of Health and Human Services (HHS) during the George W. Bush administration from 2002 to 2008. In these positions, he worked as a speechwriter and helped craft health policy for agencies including the National Institutes of Health (NIH) and the Food and Drug Administration (FDA).
Inheriting an Agency Under Pressure
O'Neill is poised to take leadership of an NSF facing significant institutional and fiscal challenges. Over the past year, the agency has undergone a substantial reduction in staff, losing approximately 30% of its workforce through early retirements and lay-offs. This was part of a broader Trump administration effort to reduce the federal workforce. The headcount has fallen from 1,717 in September 2024 to 1,198.
The agency's physical presence has also been disrupted. NSF employees are currently working remotely because the agency had to vacate its custom-built headquarters in December to make room for the US Department of Housing and Urban Development. Furthermore, the NSF faced severe budget uncertainty last year after the Trump administration proposed a 57% cut to its funding. Although Congress ultimately rejected this drastic cut and kept funding essentially flat, the proposal led to a significant decrease in new research grants, with about 20% fewer funded in 2025 compared to 2024.
From Government to Venture Capital
Following his time in the Bush administration, O'Neill moved into the private sector, where he developed a close association with billionaire investor Peter Thiel. In 2010, he played a key role in helping Thiel establish the Thiel Fellowship. This controversial program awards $200,000 grants to encourage students to leave college and pursue entrepreneurial ventures, including in science and technology fields.
O'Neill's most recent government role was as the acting head of the US Centers for Disease Control and Prevention (CDC), a position he left just last week. That role will now be filled by NIH director Jayanta Bhattacharya, who will lead both agencies simultaneously. A White House statement expressed confidence in both appointees, stating they are "eminently qualified for these positions... to deliver on the President’s agenda."
Looking Ahead
The nomination of Jim O'Neill arrives at a critical juncture for American science. The NSF's mission to fund fundamental, curiosity-driven research is at the heart of the nation's long-term technological and economic competitiveness. Stakeholders across academia and industry will be watching closely to see how O'Neill's background in biotechnology investment and government administration shapes the agency's priorities, its grant-making processes, and its relationship with the scientific community it is designed to support.
